Navidea Biopharmaceuticals (NAVB) Competitors $0.0002 0.00 (0.00%) As of 07/7/2025 10:56 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. VRPX, KRBP, MYMD, TCBP, CAPS, VINC, BON, UPC, SMFL, and HSTOShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Virpax Pharmaceuticals (VRPX), Kiromic BioPharma (KRBP), MyMD Pharmaceuticals (MYMD), TC Biopharm (TCBP), Capstone Therapeutics (CAPS), Vincerx Pharma (VINC), Bon Natural Life (BON), Universe Pharmaceuticals (UPC), Smart for Life (SMFL), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors Virpax Pharmaceuticals Kiromic BioPharma MyMD Pharmaceuticals TC Biopharm Capstone Therapeutics Vincerx Pharma Bon Natural Life Universe Pharmaceuticals Smart for Life Histogen Navidea Biopharmaceuticals (NYSE:NAVB) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Do analysts recommend NAVB or VRPX? Virpax Pharmaceuticals has a consensus target price of $75.00, suggesting a potential upside of 19,130.77%. Given Virpax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than Navidea Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, NAVB or VRPX? Navidea Biopharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K2.46-$15.18MN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Does the media prefer NAVB or VRPX? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Virpax Pharmaceuticals Neutral Is NAVB or VRPX more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% Which has more volatility & risk, NAVB or VRPX? Navidea Biopharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Do institutionals and insiders hold more shares of NAVB or VRPX? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryNavidea Biopharmaceuticals beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$20K$14.71M$5.51B$20.71BDividend YieldN/AN/A5.24%3.72%P/E RatioN/AN/A27.2127.82Price / Sales2.4614.03370.4747.03Price / CashN/AN/A26.2118.22Price / BookN/A0.027.944.59Net Income-$15.18M-$15.61M$3.17B$982.91M7 Day PerformanceN/A-10.69%1.79%0.65%1 Month PerformanceN/A-4.05%1.27%4.26%1 Year PerformanceN/A-41.68%33.56%13.93% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-80.0%$20K$8.13K0.0010Gap DownVRPXVirpax Pharmaceuticals1.34 of 5 stars$0.32+0.3%$75.00+23,634.2%-97.3%$392KN/A0.007KRBPKiromic BioPharmaN/AN/AN/AN/A$330KN/A-0.0660Gap DownHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.13+3.6%N/A-93.5%$308KN/A0.006High Trading VolumeTCBPTC BiopharmN/A$0.68-55.8%$48.00+6,948.5%-99.5%$279K$4.76M0.0080High Trading VolumeCAPSCapstone TherapeuticsN/A$1.80+7.8%N/AN/A$260K$44.88M0.0038Gap UpHigh Trading VolumeVINCVincerx Pharma2.4461 of 5 stars$0.04-12.0%$40.00+90,809.1%-99.7%$230KN/A0.0060News CoverageGap UpBONBon Natural Life1.5169 of 5 stars$1.25-0.8%N/AN/A$210K$23.84M0.00100UPCUniverse PharmaceuticalsN/A$3.75+2.7%N/A-99.8%$161K$23.02M0.00220SMFLSmart for LifeN/A$0.02-62.0%N/AN/A$108K$11.11M0.00110Gap DownHigh Trading VolumeHSTOHistogenN/A$0.01-43.5%N/A-99.9%$43K$19K0.0020Gap Down Related Companies and Tools Related Companies Virpax Pharmaceuticals Competitors Kiromic BioPharma Competitors MyMD Pharmaceuticals Competitors TC Biopharm Competitors Capstone Therapeutics Competitors Vincerx Pharma Competitors Bon Natural Life Competitors Universe Pharmaceuticals Competitors Smart for Life Competitors Histogen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
